Silence Therapeutics plc (NASDAQ:SLN) Receives Consensus Recommendation of “Buy” from Brokerages

Silence Therapeutics plc (NASDAQ:SLN) has earned an average rating of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on the stock in the last year is $57.20.

Several equities research analysts have recently commented on the company. Chardan Capital restated a “buy” rating and set a $55.00 price target on shares of Silence Therapeutics in a research note on Thursday, November 14th. Jefferies Financial Group started coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price objective for the company. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday. Morgan Stanley restated an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday.

Institutional Investors Weigh In On Silence Therapeutics

Institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. acquired a new position in Silence Therapeutics during the third quarter worth about $56,000. Quarry LP acquired a new stake in Silence Therapeutics during the second quarter valued at approximately $114,000. SG Americas Securities LLC grew its position in Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after buying an additional 667 shares during the last quarter. Verition Fund Management LLC acquired a new stake in shares of Silence Therapeutics during the 3rd quarter valued at $207,000. Finally, Custom Index Systems LLC acquired a new position in shares of Silence Therapeutics in the 2nd quarter worth $282,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Trading Down 38.0 %

Shares of Silence Therapeutics stock traded down $4.19 during trading on Tuesday, reaching $6.83. The company’s stock had a trading volume of 2,121,910 shares, compared to its average volume of 213,613. The firm has a market cap of $204.42 million, a PE ratio of -4.24 and a beta of 1.30. The company has a 50-day moving average price of $17.82 and a two-hundred day moving average price of $19.05. Silence Therapeutics has a fifty-two week low of $6.31 and a fifty-two week high of $27.72.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.